MedTrace Logo

A Randomized Control Trial Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.

NCT01067118 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-02-10

No results posted yet for this study

Summary

The purpose of this study is to determine if the use of Linjeta(tm) insulin when compared to Humalog will result in significantly lower episodes of hyperglycemia and hypoglycemia after a breakfast meal.

Conditions

Interventions

DRUG

LINjeta U-100 Insulin

LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors

DRUG

Humalog U-100

Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors

Sponsors & Collaborators

  • Biodel

    collaborator INDUSTRY

  • University of Colorado, Denver

    collaborator OTHER

  • Stanford University

    lead OTHER

Principal Investigators

  • Bruce A. Buckingham · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-01-31
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01067118 on ClinicalTrials.gov